Notably, statistics reveal that 2 years of TAM therapy can provide long‐term therapeutic benefits lasting up to 20 years for premenopausal BrC patients with estrogen receptor‐positive (ER+) tumours.114. The gene discussed is ESR1; the disease is neoplasm.